Skip to main content

Analysts Offer Insights on Technology Companies: Palo Alto Networks (PANW) and Docebo (DCBO)

Tipranks - Thu Feb 19, 9:40AM CST

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Palo Alto Networks (PANWResearch Report) and Docebo (DCBOResearch Report) with bullish sentiments.

President's Day Sale - 70% Off

Palo Alto Networks (PANW)

In a report released today, Joseph Gallo from Jefferies maintained a Buy rating on Palo Alto Networks, with a price target of $215.00. The company’s shares closed last Wednesday at $152.26.

According to TipRanks.com, Gallo is a 4-star analyst with an average return of 8.4% and a 55.0% success rate. Gallo covers the Technology sector, focusing on stocks such as CrowdStrike Holdings, Tenable Holdings, and SailPoint, Inc. ;'>

Palo Alto Networks has an analyst consensus of Strong Buy, with a price target consensus of $216.02, which is a 44.4% upside from current levels. In a report issued on February 12, TipRanks – Google also upgraded the stock to Buy with a $183.00 price target.

See the top stocks recommended by analysts >>

Docebo (DCBO)

In a report released today, George Sutton from Craig-Hallum maintained a Buy rating on Docebo. The company’s shares closed last Wednesday at $18.08.

According to TipRanks.com, Sutton is a 5-star analyst with an average return of 25.0% and a 51.7% success rate. Sutton covers the Technology sector, focusing on stocks such as DeFi Development Corporation, Applied Digital Corporation, and Core Scientific Inc. ;'>

Currently, the analyst consensus on Docebo is a Strong Buy with an average price target of $35.04.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.